Strategies to overcome host immunity to adenovirus vectors in vaccine development. - Wikidata - thesis-toulmin - TriplyDB

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

http://www.wikidata.org/entity/Q37503253

about

PEGylated Adenoviruses: From Mice to Monkeys Crystallographic Structure of Porcine Adenovirus Type 4 Fiber Head and Galectin Domains Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin Development of adenoviral vector-based mucosal vaccine against influenza.HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection Current progress in the development of a prophylactic vaccine for HIV-1.Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Structure and Sialyllactose Binding of the Carboxy-Terminal Head Domain of the Fibre from a Siadenovirus, Turkey Adenovirus 3.Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Pharmacological activation of p53 in cancer cells Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.Crystallization of the head and galectin-like domains of porcine adenovirus isolate NADC-1 fibre.Hereditary Angioedema as a Metabolic Liver Disorder: Novel Therapeutic Options and Prospects for Cure.Adenovirus: the first effective in vivo gene delivery vector Advances and future challenges in adenoviral vector pharmacology and targeting.Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.Improving T cell-induced response to subunit vaccines: opportunities for a proteomic systems approach.Applying genomic and bioinformatic resources to human adenovirus genomes for use in vaccine development and for applications in vector development for gene delivery.Crystal structure of the fibre head domain of bovine adenovirus 4, a ruminant atadenovirus.Genome Sequence of a Cynomolgus Macaque Adenovirus (CynAdV-1) Isolate from a Primate Colony in the United Kingdom Preliminary evaluation of safety of conditionally replication adenovirus M4.Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.Crystal structure of raptor adenovirus 1 fibre head and role of the beta-hairpin in siadenovirus fibre head domains.Recombinant adenovirus expressing the haemagglutinin of Peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR.Crystallization of the C-terminal head domain of the fibre protein from a siadenovirus, turkey adenovirus 3.Oral inoculation of chickens with a candidate fowl adenovirus 9 vector.

P2860

Q24635276-F3D2E05B-025E-4A44-A149-9E170104C8C3 Q27663879-22E0537D-8FE8-46E7-BA1A-9427107B5B70 Q28731982-AE178259-8002-42EC-AE09-401A2451D172 Q30396642-B8AF5B22-C35A-4B5B-9DF1-3C5BFB67D8A6 Q33646773-8AB0EC50-F315-4FE2-942D-6E0E106A1443 Q34075166-96D71D20-5D63-4E6F-8A3C-CEF7FB925C05 Q34502108-3A426315-C934-4A5C-B1BE-D95308EC88E5 Q34505337-DB355FDB-B167-43F4-8C90-5FFDC8F63CA3 Q35576891-967B0AF7-47BE-440E-8EBA-9B37F6D6E8A1 Q35666180-8B276138-0597-4CB9-B857-BD3E2A72D9AE Q35791558-3033D7DC-520C-46CC-8777-0586FF64F30D Q36326838-743CD820-E4D6-4404-803E-7D69D92EA055 Q37191174-FD7EFEDF-8574-4BE3-B328-0FF33C557A4C Q37304346-89AC89C8-345D-4F4B-A565-D0CCECAD852A Q37420351-E520D84B-1E5B-4BC2-97FC-EBC6DA9B4DE3 Q37452581-3E29A88E-EC5C-449E-91BA-753C78E9D247 Q37508260-8EDD10E5-A9B4-4AE7-8D61-CAA0C6C4CCB5 Q37859842-080AAA13-0423-4E99-9EAF-A4D4081D2E77 Q37945171-23B9726C-99AD-4AB8-8777-F4753FEB41A1 Q37974160-119666DD-7764-494D-851D-EE16A1C7F76B Q38186768-F2E516C5-1154-4A47-BB40-D05520974F31 Q38364597-F142358F-43D6-42E2-908F-8D0CACBF65CF Q38613979-1341FC49-3C21-4696-A9BB-683E70806DF1 Q39004342-2C988281-D93A-496F-B2F1-392014258CA4 Q39218445-A999D97B-D65C-4216-A398-4912D1A1B4CE Q39220073-01E9127C-6020-4A29-803A-BE289723C3E4 Q40153269-A506A11C-91F7-40F5-A95A-0F80404886C7 Q40686770-BC1454BE-F719-4EF6-B9B1-3B8D11F05FA0 Q41995734-4FFB06B2-A7CD-442A-82A6-4DE95662D32C Q41999660-188A194F-308C-4E01-A76E-D71F605C098E Q42573299-BED806C4-B476-4BA7-A51B-3B6EC7ACEE4A

P2860

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

http://www.wikidata.org/entity/Q37503253

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@en

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@nl

type

label

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@en

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@nl

prefLabel

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@en

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@nl

P1433

Q37503253-B8389764-22BD-4FF5-BDF9-27AEEA62873C

P1476

Q37503253-26E3FDD2-4908-4E68-8D7F-9478F1F99E2C

P2093

Q37503253-320C02B9-8EF3-465E-90DF-F2CAB4D81F10

Q37503253-53CBF9DF-0646-4530-A183-994D39F733A9

Q37503253-72E50F97-2224-40E6-BDDC-8542BB9B11B5

P2860

Q37503253-01735141-81A1-4E1F-94E1-46A73E8E37C4

Q37503253-020954CF-DC97-4CD8-B833-4D5816EB6F5A

Q37503253-04DE03A2-974F-42E6-AD35-E96C19ED262F

Q37503253-0569FB40-26B0-48A1-BDCA-87586D456156

Q37503253-07E33A7E-D1D1-4705-9680-3D92194C7BB7

Q37503253-09C029BE-EBC0-468D-B2CF-8B3A7AF3587B

Q37503253-0A2FB623-6795-4ECB-974C-63E10082100E

Q37503253-0B9854D8-A504-4152-85BB-61135789C336

Q37503253-0C277070-D10F-4838-998D-771A2DA7B352

Q37503253-0E627CEC-1085-4AB7-8574-C68C0FDBC70D

P304

Q37503253-48927BC5-CE2A-4C67-9D79-C4DF104DAA11

P31

Q37503253-B5A2D27E-819C-4ABC-BA42-D511F6AA80BA

P356

Q37503253-9A64F185-3E42-431C-8299-BB7CE7352857

P433

Q37503253-27B6276A-7F8D-4F38-99B7-2AEAAE512480

P478

Q37503253-CFC00EB1-86FE-4706-AA51-E22B7AA14497

P577

Q37503253-805CA9FD-3328-4423-84AB-11232EC1CE3D

P5875

Q37503253-A55781A3-9FB7-4B29-909F-3499C05BF780

P698

Q37503253-39208E94-7569-45FF-8468-2965F5E41A28

P921

Q37503253-1E67EC2E-DBCF-4FDB-9CD7-5DE6A6569B35

P932

Q37503253-1DA4C496-E3C3-4017-AEB2-4BAAABC54393

P356

P1433

Expert Review of Vaccines

P1476

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

@en

P2093

Erin E Thacker

http://www.w3.org/2001/XMLSchema#string

Laura Timares

http://www.w3.org/2001/XMLSchema#string

Qiana L Matthews

http://www.w3.org/2001/XMLSchema#string

P2860

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

The Cell Adhesion Molecule “CAR” and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo Biodistribution

Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

P304

761-777

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.09.29

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26256565

http://www.w3.org/2001/XMLSchema#string

P698

19485756

http://www.w3.org/2001/XMLSchema#string

P921

P932

3700409

http://www.w3.org/2001/XMLSchema#string